Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Comprehensive Add on Study in Japan

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Linagliptin
Drug: Metformin

First Posted Date: 2010-09-17

Last Posted Date: 2014-03-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 574

Registration Number: NCT01204294

Locations: 🇯🇵
1218.78.037 Boehringer Ingelheim Investigational Site, Higashi Osaka, Osaka, Japan
🇯🇵
1218.78.026 Boehringer Ingelheim Investigational Site, Kasugai, Aichi, Japan
🇯🇵
1218.78.038 Boehringer Ingelheim Investigational Site, Kawachinagano, Osaka, Japan

and more 40 locations

Telmisartan+Amlodipine Fixed Dose Combination in Hypertension

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: telmisartan+amlodipine fixed dose combination

First Posted Date: 2010-09-17

Last Posted Date: 2014-06-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 27

Registration Number: NCT01204398

Locations: 🇨🇳
1235.31.86001 Boehringer Ingelheim Investigational Site, Shanghai, China

Safety and Tolerability of BI 638683 After Single Rising Oral Doses in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 638683 or placebo
Drug: Placebo solution

First Posted Date: 2010-09-06

Last Posted Date: 2011-06-02

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 63

Registration Number: NCT01195688

Locations: 🇩🇪
1279.1.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Assessment of the Effect of Empagliflozin (BI 10773) as Single Dose on the QT Interval in Healthy Female and Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 10773 (low)
Drug: BI 10773 Placebo
Drug: Moxifloxacin
Drug: BI 10773 (high)

First Posted Date: 2010-09-06

Last Posted Date: 2014-07-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT01195675

Locations: 🇩🇪
1245.16.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Linagliptin
Drug: Placebo

First Posted Date: 2010-09-03

Last Posted Date: 2014-01-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 234

Registration Number: NCT01194830

Locations: 🇺🇸
1218.75.053 Boehringer Ingelheim Investigational Site, Dallas, Texas, United States
🇺🇸
1218.75.102 Boehringer Ingelheim Investigational Site, Tomball, Texas, United States
🇺🇸
1218.75.037 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States

and more 90 locations

Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: BI 10773
Drug: Placebo (mid dose)
Drug: Placebo (high dose)
Drug: Placebo (low dose)

First Posted Date: 2010-09-01

Last Posted Date: 2014-06-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 547

Registration Number: NCT01193218

Locations: 🇯🇵
1245.38.003 Boehringer Ingelheim Investigational Site, Chuo-ku, Tokyo, Japan
🇯🇵
1245.38.032 Boehringer Ingelheim Investigational Site, Okawa, Fukuoka, Japan
🇯🇵
1245.38.012 Boehringer Ingelheim Investigational Site, Sasima-gun, Ibaraki, Japan

and more 29 locations

Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients

Phase 3

Completed

Conditions: Parkinson Disease

Interventions: Drug: pramipexole extended release tablet
Drug: pramipexole immediate release tablet

First Posted Date: 2010-08-31

Last Posted Date: 2014-10-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 475

Registration Number: NCT01191944

Locations: 🇨🇳
248.671.86013 Boehringer Ingelheim Investigational Site, Chongqing, China
🇨🇳
248.671.86012 Boehringer Ingelheim Investigational Site, Chengdu, China
🇨🇳
248.671.86014 Boehringer Ingelheim Investigational Site, Chongqing, China

and more 17 locations

Study in Healthy Male Subjects to Investigate Whether Ketoconazole Affects Plasma Exposure of BI 113823

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 113823
Drug: BI 113823 + Ketokonazole

First Posted Date: 2010-08-26

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT01189175

Locations: 🇩🇪
1272.5.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 10773/linagliptin
Drug: BI 10773/linagliptin FDC
Drug: BI 10773/linagliptin SID

First Posted Date: 2010-08-26

Last Posted Date: 2015-03-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 42

Registration Number: NCT01189201

Locations: 🇩🇪
1275.3.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Phase 4

Completed

Conditions: Arthroplasty, Replacement
Prevention of Venous Thromboembolism
Moderate Renal Impairment (CrCl 30-50 mL/Min)

Interventions: Drug: Dabigatran etexilate

First Posted Date: 2010-08-19

Last Posted Date: 2018-09-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 142

Registration Number: NCT01184989

Locations: 🇫🇮
1160.86.35801 Boehringer Ingelheim Investigational Site, Jyväskylä, Finland
🇨🇦
1160.86.01001 Boehringer Ingelheim Investigational Site, Red Deer, Alberta, Canada
🇨🇦
1160.86.01002 Boehringer Ingelheim Investigational Site, Halifax, Nova Scotia, Canada

and more 7 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy